Animal-Facilitated Therapy in Various Patient Populations Systematic Literature Review Sarah Matuszek, MSN, RN
... were discovered but not used for this literature review. The basis of this systematic literature review was to examine the effects of animal therapy on patients in various nursing care environments and to discover implications that nurses can use in their care. In order to be included in this review ...
... were discovered but not used for this literature review. The basis of this systematic literature review was to examine the effects of animal therapy on patients in various nursing care environments and to discover implications that nurses can use in their care. In order to be included in this review ...
Is There a Place for Placebo in Management of Psychogenic
... studies have shown that dopamine is released in response to placebo given to patients with Parkinson’s disease,8 which might explain the physiologic basis for the placebo effect, at least in part.8 Endogenous opioid production had earlier been invoked to explain the placebo effect in analgesia.8 Not ...
... studies have shown that dopamine is released in response to placebo given to patients with Parkinson’s disease,8 which might explain the physiologic basis for the placebo effect, at least in part.8 Endogenous opioid production had earlier been invoked to explain the placebo effect in analgesia.8 Not ...
Personality Traits of Schizophrenic Patients in Remission and Their
... V.A., A.G.: The authors reported no conflict of interest related to this article. ...
... V.A., A.G.: The authors reported no conflict of interest related to this article. ...
Molecular Genetics of Autosomal-Dominant Demyelinating Charcot
... the control of their own regulatory elements, show similar dose-dependent dysmyelinating and demyelinating neuropathies to those observed in human patients (Magyar et al., 1996; Sereda et al., 1996; Sancho et al., 1999). Afurther interesting transgenic mouse model was developed in which the overexpr ...
... the control of their own regulatory elements, show similar dose-dependent dysmyelinating and demyelinating neuropathies to those observed in human patients (Magyar et al., 1996; Sereda et al., 1996; Sancho et al., 1999). Afurther interesting transgenic mouse model was developed in which the overexpr ...
Isolation and characterization of Viviparous
... most cases encode aberrant translation products (McKibbin et al., 2002). Comparison of the transcript structures of wheat and closely related wild and ancestral species suggest that mis-splicing of Vp-1 genes might occur before the evolution and domestication of common wheat (McKibbin et al., 2002). ...
... most cases encode aberrant translation products (McKibbin et al., 2002). Comparison of the transcript structures of wheat and closely related wild and ancestral species suggest that mis-splicing of Vp-1 genes might occur before the evolution and domestication of common wheat (McKibbin et al., 2002). ...
SGD sample annotations
... genes, we do occasionally add large sets of GO annotations derived from large scale studies. For us to be able to make GO annotations from a large scale study, typically the authors must have used some sort of controlled vocabulary to describe their results, where curators can map at least some of t ...
... genes, we do occasionally add large sets of GO annotations derived from large scale studies. For us to be able to make GO annotations from a large scale study, typically the authors must have used some sort of controlled vocabulary to describe their results, where curators can map at least some of t ...
IMPLICATIONS OF GENETIC TESTING ON HEMOCHROMATOSIS
... whether or not he or she has cirrhosis. Do we always need to do a biopsy? The answer is no. This is a study we published several years ago; the yellow dots have cirrhosis, the open circles don’t have cirrhosis. You can see that if the AST is normal and the ferritin is under 1000, nobody had cirrhosi ...
... whether or not he or she has cirrhosis. Do we always need to do a biopsy? The answer is no. This is a study we published several years ago; the yellow dots have cirrhosis, the open circles don’t have cirrhosis. You can see that if the AST is normal and the ferritin is under 1000, nobody had cirrhosi ...
SOP Criteria for Variant Classification
... Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) Caveat: As many in silico algorithms use the same or very similar input for their predictions, each algorithm cannot be counted as an independent criterion. BP4 can b ...
... Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc) Caveat: As many in silico algorithms use the same or very similar input for their predictions, each algorithm cannot be counted as an independent criterion. BP4 can b ...
Loss of Heterozygosity at 6q Is Frequent and Concurrent with 3p
... and suppressed colony-forming ability in soft agar as well as tumor development in nude mice (44). Therefore, the human LATS1 gene may also play an important role in suppressing tumor formation in humans (43, 44). A third interesting tumor suppressor gene located at 6q24–25 is ZAC (zinc finger C2 pr ...
... and suppressed colony-forming ability in soft agar as well as tumor development in nude mice (44). Therefore, the human LATS1 gene may also play an important role in suppressing tumor formation in humans (43, 44). A third interesting tumor suppressor gene located at 6q24–25 is ZAC (zinc finger C2 pr ...
Liver Cirrhosis
... treated with chelation therapy (for example, penicillamine) to remove the copper. o Preventing further liver damage • Regardless of underlying cause of cirrhosis, alcohol and paracetamol, as well as other potentially damaging substances, are discouraged. Vaccination of susceptible patients should be ...
... treated with chelation therapy (for example, penicillamine) to remove the copper. o Preventing further liver damage • Regardless of underlying cause of cirrhosis, alcohol and paracetamol, as well as other potentially damaging substances, are discouraged. Vaccination of susceptible patients should be ...
Genetic and Molecular Diagnostics – Next Generation Sequencing
... II. If the test in question is not part of Table 3, see Table 1 for a state listing to determine if the laboratory is located in a geographical area that has adopted MolDX guidelines. a. For Medicare jurisdictions which HAVE adopted MolDX Program guidelines: i. The MolDX Program has determined certa ...
... II. If the test in question is not part of Table 3, see Table 1 for a state listing to determine if the laboratory is located in a geographical area that has adopted MolDX guidelines. a. For Medicare jurisdictions which HAVE adopted MolDX Program guidelines: i. The MolDX Program has determined certa ...
Gene expression in early and progression phases of autosomal
... with the microarray results (Figure 2A). Transcriptome Alteration in Pkd1L3/L3 Kidney in the Early Phase of ADPKD An original goal of this study was to identify gene expression alterations in Pkd1L3/L3 kidney during the initial and progressive phases, which may represent specific landmarks in a mole ...
... with the microarray results (Figure 2A). Transcriptome Alteration in Pkd1L3/L3 Kidney in the Early Phase of ADPKD An original goal of this study was to identify gene expression alterations in Pkd1L3/L3 kidney during the initial and progressive phases, which may represent specific landmarks in a mole ...
New Patient Forms for Massage
... I understand that massage therapy performed by a licensed massage therapist is intended but not limited to: enhance relaxation, reduce pain caused by muscle tension, increase range of motion and improve circulation. I understand that massage therapy is not a substitute for medical treatment or medic ...
... I understand that massage therapy performed by a licensed massage therapist is intended but not limited to: enhance relaxation, reduce pain caused by muscle tension, increase range of motion and improve circulation. I understand that massage therapy is not a substitute for medical treatment or medic ...
principles of evidence-based physical therapy practice
... in these situations were observed to have an increased risk of heart disease that, from a biological perspective, appeared connected to the loss of estrogen and progestin. Replacing the lost hormones in an effort to reduce the risk of heart disease in these women made sense. The success of this trea ...
... in these situations were observed to have an increased risk of heart disease that, from a biological perspective, appeared connected to the loss of estrogen and progestin. Replacing the lost hormones in an effort to reduce the risk of heart disease in these women made sense. The success of this trea ...
Case study # 39 Keith Fehring, BA 2009 Andre Jakoi, BS 2008
... patient is homozygous of heterozygous for the abnormal FGFR3 gene. Currently, there is no cure or specific treatment for achondroplasia, but many treatments have been used with varied success. Pharmacologic, as well as surgical therapies are available if needed. It is important to monitor the pat ...
... patient is homozygous of heterozygous for the abnormal FGFR3 gene. Currently, there is no cure or specific treatment for achondroplasia, but many treatments have been used with varied success. Pharmacologic, as well as surgical therapies are available if needed. It is important to monitor the pat ...
Against the Central Dogma
... exogenous replacement. Additionally, flies have hundreds of binding sites for these lncRNAs throughout the X chromosome with differing affinities, suggesting they can exert their upregulatory effects to differing degrees. ...
... exogenous replacement. Additionally, flies have hundreds of binding sites for these lncRNAs throughout the X chromosome with differing affinities, suggesting they can exert their upregulatory effects to differing degrees. ...
Determination of IL-23 receptor gene polymorphism in Iranian
... the most common genetic factor involved in the initiation and pathology of this disease. It is estimated that up to 90% of patients with AS could be HLA-B27-positive in most ethnic populations throughout the world; however, only 2% of HLA-B27-positive individuals in the general populations could be ...
... the most common genetic factor involved in the initiation and pathology of this disease. It is estimated that up to 90% of patients with AS could be HLA-B27-positive in most ethnic populations throughout the world; however, only 2% of HLA-B27-positive individuals in the general populations could be ...
Acute Myelogenous Leukemia: A Guide for Patients and Caregivers
... the patient’s arm with a needle. The blood is collected in tubes and sent to a lab. A bone marrow aspiration is done by removing a sample of cells from the marrow. A bone marrow biopsy is done by removing a very small amount of bone filled with marrow cells. Both tests are done with a special needle ...
... the patient’s arm with a needle. The blood is collected in tubes and sent to a lab. A bone marrow aspiration is done by removing a sample of cells from the marrow. A bone marrow biopsy is done by removing a very small amount of bone filled with marrow cells. Both tests are done with a special needle ...
GENETIC CHARACTERIZATION OF NITRA RABBITS AND ZOBOR
... In an attempt to characterize the two rabbit breeds concerning the shift on the genetic level we studied microsatellite and genetic markers associated with coat color. These two local rabbit breeds, Nitra rabbit (Ni) and Zobor rabbit (Zo) with different phenotypes have a common origin. Based on the ...
... In an attempt to characterize the two rabbit breeds concerning the shift on the genetic level we studied microsatellite and genetic markers associated with coat color. These two local rabbit breeds, Nitra rabbit (Ni) and Zobor rabbit (Zo) with different phenotypes have a common origin. Based on the ...
Current Microbiology
... identified as yet [4]. The missing hoxF gene, as well as hoxE, will be described in the present communication. HoxE, F and U show significant sequence similarities to three subunits of the mitochondrial complex I (NADH:Q oxidoreductase) and the corresponding subunits NuoE, F, and G in E. coli [2, 25 ...
... identified as yet [4]. The missing hoxF gene, as well as hoxE, will be described in the present communication. HoxE, F and U show significant sequence similarities to three subunits of the mitochondrial complex I (NADH:Q oxidoreductase) and the corresponding subunits NuoE, F, and G in E. coli [2, 25 ...
Biotechnology Webquest
... 14. Discuss what is meant by the phrase “altered genes”. 15. What are “genetic metabolic diseases”? http://www.accessexcellence.org/RC/AB/BA/aapost/genetherapy.html 16. What is Gene Therapy? 17. How can it be used to assist children with cystic fibrosis? http://www.accessexcellence.org/RC/AB/BA/The_ ...
... 14. Discuss what is meant by the phrase “altered genes”. 15. What are “genetic metabolic diseases”? http://www.accessexcellence.org/RC/AB/BA/aapost/genetherapy.html 16. What is Gene Therapy? 17. How can it be used to assist children with cystic fibrosis? http://www.accessexcellence.org/RC/AB/BA/The_ ...
Gene therapy
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. Gene therapy could be a way to fix a genetic problem at its source. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a ""vector"", which carries the molecule inside cells.Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. By the late 1980s the technology had already been extensively used on animals, and the first genetic modification of a living human occurred on a trial basis in May 1989 , and the first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred on September 14, 1990, when Ashanti DeSilva was treated for ADA-SCID. By January 2014, some 2,000 clinical trials had been conducted or approved.Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal disease Leber's congenital amaurosis, X-linked SCID, ADA-SCID, adrenoleukodystrophy, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), multiple myeloma, haemophilia and Parkinson's disease. Between 2013 and April 2014, US companies invested over $600 million in the field.The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia.In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.